Slingshot members are tracking this corporate initiative:
Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
Do you think this event is important to the companies below? How will it affect their stock price?
Under the terms of the collaboration agreement, Precision will be primarily responsible for the development, formulation, and preclinical evaluation of the investigational nucleases, and Gilead will be responsible for the clinical development and commercialization of potential therapies. Gilead will fully fund the research and development. Precision is eligible to receive milestone payments of up to an aggregate of $445 million and tiered royalties that go up to the mid-teens for commercial products developed through the collaboration.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Sep 12, 2018 Projected Implementation: Q3, 2018 Relevance Tracked Until: Q4, 2018
Don’t see a project related to the strategic initiative you care about?
Related Keywords Hepatitis B, Arcus, Genome Editing